Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Burris

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Seminars in Oncology|April 13, 2001
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancerH A Burris
Seminars in Hematology|January 6, 2000
The evolving role of oral topotecanH A Burris
Seminars in Oncology|May 16, 2000
Docetaxel (Taxotere) in the treatment of cancerH A Burris
Seminars in Oncology|May 16, 2000
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)H A Burris
Oncogene|August 15, 2009
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needsH A Burris
Seminars in Oncology|July 30, 1999
Single-agent docetaxel (Taxotere) in randomized phase III trialsH A Burris
Oncology (Williston Park, N.Y.)|August 1, 1997
Docetaxel in combination with fluorouracil for advanced solid tumorsH A Burris
Oncology (Williston Park, N.Y.)|November 1, 1996
Objective outcome measures of quality of lifeH A Burris
Anti-Cancer Drugs|August 1, 1996
Optimal use of docetaxel (Taxotere): maximizing its potentialH A Burris
The Annals of Pharmacotherapy|May 1, 1994
Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trialsH A Burris
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Seminars in Oncology|April 13, 2001
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancerH A Burris
Seminars in Hematology|January 6, 2000
The evolving role of oral topotecanH A Burris
Seminars in Oncology|May 16, 2000
Docetaxel (Taxotere) in the treatment of cancerH A Burris
Seminars in Oncology|May 16, 2000
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)H A Burris
Oncogene|August 15, 2009
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needsH A Burris
Seminars in Oncology|July 30, 1999
Single-agent docetaxel (Taxotere) in randomized phase III trialsH A Burris
Oncology (Williston Park, N.Y.)|August 1, 1997
Docetaxel in combination with fluorouracil for advanced solid tumorsH A Burris
Oncology (Williston Park, N.Y.)|November 1, 1996
Objective outcome measures of quality of lifeH A Burris
Anti-Cancer Drugs|August 1, 1996
Optimal use of docetaxel (Taxotere): maximizing its potentialH A Burris
The Annals of Pharmacotherapy|May 1, 1994
Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trialsH A Burris
Pageof 12